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Abstract
We analysed the clinical and hematological features in 41 patients of seven families, including 21 ET patients with
a proven MPLS505N mutation and 20 relatives with thrombocythemia reported in the medical records. Out of the 41
MPLS505N mutated individuals 15 major thrombotic episodes in 14 members (34%) were reported as Budd-Chiari
syndrome age 17 in 1, deep vein thrombosis leg age 41 in 1,ecclampsia and fetal in 1, stroke at ages 43, 72, 76 and
80 in 4 and myocardial infarction at ages between 31-81 years, median 52 years. Fourteen out of 21 well
documented MPLS505N mutated ET patients had no splenomegaly and were free of major thrombosis during
follow-up at ages between 2 and 76 years (mean 31 years). Eight MPLS505N mutated patients had myelofibrosis
(MF) from grade MF1 in 5 to grade MF2 in 3 at ages between 28-80 years (mean 48 years), which was associated
with mild to moderate splenomegaly (spleen length diameter 14.5 to 18 cm). Six anemic cases at hemoglobin levels
between 10 and 11.9 g/dL had platelet counts between 317 and 963 × 109/L. Among 15 family members 9 died from
thrombosis in 3, hypocellular myelofibrosis (two of them at age 76 and 80 years) in 3, and cancer or undefined in 3
cases. The maximum life expectancy of MPLS505N family members with thrombocythemia was 50% at 80 years, and
90% at 80 years of non-affected family members without thrombocythemia. The clinical presentation in 30 ET
patients with acquired MPL505N mutation (9 males and 21 females, age 22-84 (mean 56 years of whom 18 had the
W515L and 12 the W515K) was featured by a high incidence of major arterial event in 23%, venous thrombosis in
10%, aspirin responsive microvessel disturbances in 60%, and major hemorrhage in 7%. The only abnormal
laboratory finding in MPL mutated ET was increased platelet counts, 956+331 × 109/L in all and slight splenomegaly
in 5 (17%). Bone marrow histology from patients ET carrying the MPL505N mutation consistently displayed a
normocellular bone marrow with clustered small and large to giant megakaryocytes with hyperlobulated stag-horn
nuclei and no features of polycythemia vera (PV) in blood and bone marrow.
Keywords: Myeloproliferative Neoplasm; Essential
Thrombocythemia; Myelofibrosis; Congenital or acquired MPL
mutations.
Introduction
In the 1990s, studies on murine leukemia and oncogenes led to the
recognition of a new member of the hematopoietin receptor super
family [1], which was discovered as the product of the gene c-mpl, the
normal cellular homologue of the oncogene v-cmpl, the transforming
principle of a murine myeloproliferative leukemia virus, responsible
for a panmyloid transformation [2]. This was followed by the
molecular cloning and characterisation of Mpl, the human homologue
of the c-mpl and v-mpl [3-5]. The new receptor was than rapidly
recognized as being the thrombopoietin receptor (TpoR) by the
demonstration that antisense oligonucleotides of c-mpl inhibited the
colony-forming of megakaryocyte progenitors by Wendling and
Vainchenker [4]. The Mpl ligand became the key to the identification
of TPO, which was cloned in 1994 by five independent groups [6-11].
The MPL ligand is identical to TpoR and labeled as megakaryocyte
growth and development factor (MDGF) [10-13]. Human TPO has all
the functions ascribed to MDGF, and all MDGF-like activity can be
neutralized by soluble recombinant Mp [1].
Thrombopoietine (TPO) is encoded by the human TPO gene and
located on chromosome 3q271. The mature TPO molecule is
composed of 32 amino acids. The TPO Receptor (TpoR) is encoded by
the myeloproliferative leukemia (MPL) gene, which is located on
chromosome 1p34. TPO and its ligand MPL are involved in nearly
every step of megakaryocyte development including mobilisation of
hematopoietic stem cells, stimulating megakaryocyte proliferation and
lineage differentiation. TPO deficient mice show a marked decrease in
the number of megakaryocytes and platelets, accompanied by
significant reduction of all lineage hematopoietic progenitor cells
[14-16]. These animals are the counterpart of congenital recessive
amegakaryocyte thrombocythemia (CAMT), a pedriatric disease
resulting from the loss of function of the MPL gene in newborns with
recessive severe thrombocytopenia who later develop severa anemia in
Journal of Hematology &
Thromboembolic Diseases Michiels et al., J Hematol Thrombo Dis 2014, 2:6http://dx.doi.org/10.4172/2329-8790.1000181
Research Article Open Access
J Hematol Thrombo Dis
ISSN:2329-8790 JHTD, an open access journal Volume 2 • Issue 6 • 1000181
early childhood. TpoR or MPL exists as a transmembrane receoptor in
megakaryocytes and platelets, that has no intrinsic kinase activity, but
associates with the cytoplasmic tyrokinase JAK2. Upon TPO ligand
binding the TpoR/MPL receptor undergoes a conformational shift
followed by cross-activation of two JAK2 molecules. TPO stimulation
results in phophorysation of MPL-bound JAKs and the subsequent
activation of several down-stream pathways.
Megakaryopoiesis Plasma TPO, TPOR/CMPL Receptor
and Platelet Production
TPO messenger studies showed that the main site of TPO
production is in the liver and kidneys, an expression pattern similar to
EPO [1]. It is known that hepatoblastoma and nephroblastoma may be
accompanied by thrombocytosis due to increased TPO production
and increased plasma TPO levels. During megakaryopoiesis the
hematopoietic stem cell pass through a stage that they are still bipotent
and have the capacity to become either erythroid cells or
megakaryocytes under the influence of EPO and TPO respectively.
The megakaryoblasts undergo a number of endomitotic reduplications
and mainly megakaryocytes with 16-32N chromosomes and only a few
64-128N (hyperploidization) chromosomes are formed [1]. The last
stage I the formation of filamentous extrusions called proplatelets,
which fragment into platelets. TPO levels in serum are about three to
four times higher than in EDTA plasma, because TPO is stored in
platelets in high concentration and released during coagulation.
Plasma TPO levels in various blood and coagulation disorders
reveal an inverse relationship between amegakaryocytic
thrombocytopenia due to loss of function mutation of cMPL (Figure
1) [1]. In patients with pancytopenia and thrombocytopenia caused by
acute myleloid leukemia (AML) or myelodysplastic syndrome (MDS)
TPO levels are high (Figure 2) very likely due megakaryocytopenia in
the bone marrow [1].
Plasma TPO levels are normal in immune thrombocytopenia due to
an increased platelet destruction (Figure 2) and in patients with
increased platelet count in reactive thrombocytosis and in essential
thrombocythemia. This contrasts with low EPO levels concentrations
found in JAK2V617F mutated ET, prodromal PV and classical PV.
Plasma TPO levels in ET (JAK2V617F positive and JAK2 wild type)
are not down regulated. This difference reflects the fact that EPO is
regulated at the level of production, while TPO is regulated largely by
binding to platelets and their rate of peripheral consumption. In most
clinical studies serum is used thus not only free plasma TPO, Serum
TPO measures the total of plasma TPO plus TPO released from
platelets during blood coagulation.
In ET this may lead to the measurement of high serum TPO
concentrations in ET. Von den Borne found that plasma TPO levels in
essential thrombocythemia are not increased (Figure 2) [1].
Figure 1: Plasma TPO levels in controls and in various groups of
patients thrombocytopenia thrombocytopenia: ITP=idiopathic
autoimmune thrombocytopenia; Sec ITP secondary autoimmune
thrombocytopenia; Ameg TP=amegakaryocytic thrombocytopenia;
Miscell A=acquired thrombocytopenia of non-immune cause but
with a normal bone marrow; Miscel B=acquired thrombocytopenia
of non-immune cause with a depressed bone marrow. Plasma TPO
levels in the normal controls are 2.2-35 AU/ml. Von Dem Borne et
al. 1998.
Figure 2: Relationship between plasma TPO level and decreased
platelet count in patients with pancytopenia caused by acute myloid
leukemia (AML) and myelodysplastic syndrome (MDS).
No .increased Plasma TPO levels in 18 patients with acquired
essential throbocythemia. Normal=upper limit of normal.
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Figure 3: Hematotoxylin-eosin (H&E) and silver staining of poor
quality bone marrow biopsies from 3 patients with autosomal
dominant hereditary thrombocythemia caused by MPLS505N
mutation at young, adult and old age. A and B, age 16 years.
Hypercellular (100%) ET with increased neutrophils and loose
clusters of atypical megakaryocytes and normal erythropoiesis and
increase of reticulin fibers RF grade 0/1. C and D, age 43 years.
Moderatetely hypercellular (70%) ET with dense clusters of atypical
megakaryocytes and increase of RF 2. E and F, age 69 years.
Hypocelluar with numerous distorted megakaryocytes and diffuse
increase in reticulin fibers with focal bundles of collagen RF grade
3/4, MF-3 with osteosclerosis. These 3 stages of atypical evolution
megakaryopoiesis and increase of RF reflect the natural history of
MPLS505N ET into hypocellular secondary MF.
Congenital Het Caused by the MPLSER505ASN Mutation
Congenital gain of function mutation in the TPO gene on
chromosome 3q27 results in increased levels of plasma TPO levels,
which induce a physiological activation of the TPO?TPOR/MPL
signalling pathway in three reported families with hereditary essential
thrombocythemia [17-20]. This results in hyperproliferation of large
mature megakaryocytes and platelet count complicated by platelet-
mediated microvascular complications. In a previous report we
reviewed the presenting features and the natural history of two
families with hereditary ET (HET) and secondary myelofibrosis caused
by a gain of function mutation in the TPO gene [21]. In 2004 Ding et
al. described the first case of congenital ET in the pedigree of a
Japanese family caused by a G to A nucleotide substitution at position
1073 in exon 10 of the MPL gene leading to the exchange os serine for
asparaginase at position 505 (MPLS505N) [22]. Ding et al. demonstrated
that the presence of the germ line MPLS505N mutation is associated
with autonomous activation in the MPL downstream signaling
pathways, both in vitro in cells transfected with the mutant and in vivo
in platelets obtained from affected individuals. The authors clearly
demonstrated that cells expressing MPLS505N showed autonomous
phosphorylation of both Mek1/2 and Stat5 down signaling
transduction pathways but the clinical course of the disease in terms of
vascular complications were not reported in family members carrying
the MPLS505N mutation.
Teofili et al. described in 2010 eight Italian families positive for the
MPLS505N mutation and reported on the clinical manifestations and
hematological features in 41 patients of seven families, including 21 ET
patients with a proven MPLS505N mutation and 20 relatives with
thrombocytosis [23]. The family history of 41 individuals reported 15
major thrombotic episodes in 14 members (34%): Budd-Chiari
syndrome age 17 in 1, deep vein thrombosis leg age 41 in 1,ecclampsia
and fetal in 1, stroke at ages 43,72, 76 and 80 in 4 and myocardial
infarction at ages between 31-81 years, median 52 years. These patients
were not on aspirin at time of the occurrence of major thrombotic
event and after a major thrombotic event they were treated with
hydroxyurea or pegylated interferon (IFN) according to Italian
guidelines (high thrombotic risk ELN) [24]. The overall survival and
thrombosis-free survival in 41 affected family members with
hereditary ET with MPLS505N thrombocythemia (Family members
with thrombocytosis, Figure 3) was compromized as compared to
normal overall and thrombosis-free survival in non-affected family
members without thrombocythemia (Family members without
thrombocytosis, Figure 4). Clinical manifestation of aspirin responsive
microvascular disturbances including erythromelalgia, migraine-like
atypical cerebral transient ischemic attacks (MIAs) and visual ischemic
disturbances usually precede the occurrence of major thrombosis in
ET and PV when not on aspirin. The indication of aspirin in 15 out of
21 MPLS505N mutated ET cases was headache not otherwise specified,
and none experienced bleeding complications during follow-up.
Fourteen out of 21 documented MPLS505N carriers were free of major
thrombosis during follow-up at ages between 2 and 76 years (2, 4, 7,
20, 25, 28, 31, 34, 42, 69 and 76 years). There was no splenomegaly in
13 these 14 cases without a history of thrombosis.
Three stages of atypical evolution megakaryopoiesis and increase of
RF in bone marrow biopsies reflecting the natural history of MPLS505N
ET from normocelluar or hypercellular ET into hypocellular
secondary MF is shown in Figure 3.
At age 16 years a hypercellular (100%) ET with increased
neutrophils and loose clusters of atypical megakaryocytes ws
associated with and normal erythropoiesis and increase of reticulin
fibers RF grade 0/1.
At age 43 years moderate hypercellularity (70%) in ET and dense
clusters of atypical megakaryocytes was associated with an increase of
reticuin fibers grade 2 (RF 2=MF 1).
At age 69 years a hypocelluar bone marrow with numerous
distorted megakaryocytes was associated with diffuse increase in
reticulin fibers (RF grade 3 to 4) and focal bundles of collagen
myelofibrosis MF-3 with osteosclerosis.
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Figure 4: Compromized overall survival and thrombosis-free
survival in 41 affected family members with hereditary ET with
documented MPLS505N thrombocythemia or reported
thrombocytosis (Family members with thrombocytosis) as
compared to normal overall and thrombosis-free survival in non-
affected family members without thrombocytosis (Famiy members
without thrombocytosis.
In this cohort of 21 MPLS505N patients four cases presented with
major thrombosis (19%); stroke at age 76 and 80 in 2, DVT/TIA at age
41/43 in 1 and myocardial infraction at age 31 in 1. Eight MPLS505N
patients had myelofibrosis (MF) [25] grade MF1 in 5 and grade MF2
in 3 at ages 76, 55, 80, 28, 23, 33, 67, which was associated with mild to
moderate splenomegaly (spleen length diameter 14.5 to 18 cm). Five of
these MF patients were treated for several years with hydroxyurea
(HU) in 3, interferon (IFN) in 1 and HU/IF in 1, and four of these five
MF cases had anemia as a side effect of hydroxyurea and/or
myelofibrotic transformation. All MF1 or MF2 patients had normal
leukocyte counts counts except one female at age 72 years. Six anemic
cases at hemoglobin levels between 10 and 11.9 g/dL had platelet
counts between 317 and 963 × 109/L. At hemoglobin levels above 12
g/dl platelet counts ranged from 605 to 1726 × 109/L. Leukocyte
counts were completely normal except leucocytosis above 10 in 3
young affected children (age 4 to 7 years) and one female at age 72.
Among 15 family members 9 died prematurely of major thrombosis in
3, anemia with hypocellular myelofibrosis (2 cases at age 76 and 80
years, Figure 3), and liver cirrhosis, gastric cancer or undefined in 1
case each. Comparing all family members without thrombocythemia
the overall survival and thrombosis-free survival was significantly
shortened in MPLS505N mutated thrombocythemia patients. The
maximum life expectancy of MPLS505N family members with
thrombocythemia was 50% at 80 years, and 90% at 80 years of non-
affetected family members without thrombocythemia (Figure 4). This
analysis strongly suggest that the loss of life expectancy is mainly due
to major thrombosis and myelofibrotic transformation since 2 of 3
MPLS505N cases died from hypocellular myelofibrosis died at old ages
of 76 and 80 years.
Acquired MPL515 mutated Essential
Thrombocythemmia
The JAK2 kinase activity in MPN is not only dependent on the
amount of heterozygous and homozygous JAK2V617F mutant protein,
but may also be influenced by the various steps upstream or
downstream the signalling pathways including MPL, JAK2, STAT-3.
This has been demonstrated in animal models overexpressing c-MPL
[8,9]. MPL transgenic mice manifested with typical features of ET with
a fourfold increase of platelet count, increased colony formation of
megakaryocytes, and increase of clustered enlarged megakaryocytes in
the bone marrow. The ET animals appeared healthy, had a very slight
decrease of hematocrit (0.39 versus 0.42 in controls) despite an
increase of bone marrow EEC, and survived normally with no
evidence of myelofibrosis in the bone marrow [8,9]. The first case of
congenital ET by Ding et al. in 2004 in a Japanese family caused by the
germline MPLS505N mutation [22] and the discovery of the JAK2V617F
mutation by Vainchenker et al. in 200526 as the cause of ET and PV
has led to the discovery of the MPLW515L and MPLW515K.somatic
mutations as the cause of acquired ET and secondary myelofibrosis
[26-29]. Within the JAK2 wild type MPN, there is a small subgroup
who carry an acquired gain of function mutation of the MPL receptor
as the cause of ET: 3% in the Vannucchi study [29], and 8.5% in the
UK studies [30,31]. In contrast to JAK2V617F mutated trilinear MPN,
patients with JAK2 wild type PT carrying the MPL515 mutation have
no clinical, laboratory and bone marrow features of prodromal PV at
diagnosis, do not evolve into overt PV during follow-up, have normal
serum EPO and ferritin levels, and show pronounced megakaryoctic
proliferation of small and large (giant) megakarocytes and no increase
of erythropoiesis in the bone marrow [29].
Vannucchi et al. studied [30] Essential Thrombocthemia (ET)
patients carrying the MPL515 mutation, 9 males and 21 females, age
22-84 (mean 56) years [29]. The clinical presentation at diagnosis and
follow-up was remarkable with a high incidence of major arterial
event, 23%, venous thrombosis, 10%, microvessel disturbances, 60%,
and major hemorrhage, 7%. The only abnormal laboratory finding was
increased platelet counts, 956+331 × 109/L together with hemoglobin
values in the lower range of normal (13.4+1.3 g/l), normal white blood
cells (8.8+3.1 × 109/L), slight increase of LDH (459+182 U/L) and
splenomegaly in only 5 (17%) of 30 MPL515 mutated ET cases of
whom 18 had the W515L and 12 the W515K allele mutated. Mutation
allele burden was greater than 50% in half of MPLW515K patients
compared to 17% of MPLW515L mutated ET patients. MPL515 and
JAK2V617F mutations coexisted in 3 with MPLW515L and in 5 with
MPLW515K allele mutations. General features of bone marrow reports
revealed significantly reduced erythropoiesis and decreased cellularity
in MPLW515L/K patients, associated with increased number of clustered
small and large megakaryocytes, but no significant increase in reticulin
fibrosis (RF). Activation of MPL by thrombopoietin enhances normal
platelet function and abnormal activation of ET platelets by
thrombopoietin preincubation has been described by Akkerman et al.
[32]. Consequently, Vannucchi et al. hypothesized that platelets from
MPLW515L/K mutated ET patients present consitutively enhanced
reactivity (hypersensitive) of the mutated platelets to explain the high
incidence of aspirin responsive microvascular disturbances and major
arterial thrombotic events in acquired MPL mutated ET [29]. The
Dutch family with hereditary ET due to a gain of function mutation in
the TPO gene had life-long increased plasma TPO levels and presented
at young and adult age recurrent erythromelalgia complicated by
acrocyanosis of a few toes followed by gangrene and amputation of
toe, which typically responded to low dose aspirin but not by
Coumadin [21] thereby preventing the occurrence of major
thrombotic during lifelong follow-up.
Bone Marrow Histology in Acquired MPL515 Mutated
ET and MF
In 2008 we studied bone marrow histopathology in 12 cases with
JAK2 wild type ET carrying the MPL515 mutation kindly provided by
the courtesy of Dr. Vannucchi, Florence, Italy. Bone marrow histology
from patients with JAK2 wild type ET carrying the MPL515 mutation
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consistently displayed clusters small and large megakaryocytes with a
greater number of giant megakaryocytes with hyperlobulated stag-
horn nuclei in a normal cellular bone marrow and no increase of
erythropoiesis. Bone marrow histology of two representative cases of
MPL515 mutated ET are shown Figures 5 and 6.
As compared to bone marrow histopathology in JAK2V617F mutated
ET (Figure 7) there were significant differences on three points. First,
the megakaryocytes in MPL515 mutated PT are larger than in ET and
PV (Figures 5 and 6), whereas the megakaryocytes in JAK2V617F
mutated ET are not larger than in PV and show similar pleomorphic
megakaryocytes morphology as in PV (Figure 7).
Second, there was local increase of erythropoiesis in areas of loose
clustered pleiomorphic megakaryoctyes in JAK2V617F mutated ET
(Figure 7), but not in JAK2 wild type PT carrying the MPL515
mutation.
Whether such differences of megakaryocyte morphology in bone
marrow biopsies are characteristic enough to distinguish
normocellular ET with low JAK2 mutation load from JAK2 wild type
ET carrying the MPL515 mutation respectively by expert
hematopathologists remains to be evaluated in prospective clinical and
basic research studies.
Figure 5: JAK2 wild type ET carrying the MPL515 mutation with
loose clustered small, large and giant mature megakaryocytes with
the presence of hyperlobulated, “stag-horn” hyperlobulated
nucleus. ET Case 1, upper panel and ET case 2, lower panel.
Courtesy of Dr. Vannucchi.
Figure 6: JAK2 wild type ET carrying the MPL515 mutation with
features of ET (WHO-ET) with the presence of clustered large and
giant megakaryocytes and increase of reticulin fibrosis grade 2/3
(RF 2/3). Such increase of RF in a rather normocellular (65%) bone
marrow is not seen in ET and PV carrying the JAK2V617F and also
not in JAK2 wild type hypercellular ET due to PMGM ET case 3,
Courtesy of Dr. Vannucchi.
Figure 7: Bone marrow histology in 59 cases of JAK2V617F mutated
ET versus 44 cases of JAK2 wild type ET according to Pich et al.
JAK2 wild ET patients in the study of Pich et al. are predicted to
carry one of the CALR or MPL515 mutations.
Case Report on the Natural History of MPL515 Mutated
ET
We studied the natural history of a 41-year old woman born in 1995
who presented in January 1996 with MPLW515L mutated ET and a one
year history of tingling prickling sensations in fingers and hand,
vertigo and attacks of frontal headaches. Laboratory features at time of
diagnosis were, hemoglobin 12.8 g/L, hematocrit 0.39, leukocytes 7.5 ×
109/L, normal LDH and spleen size on echogram 12.6 cm (normal
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value <12 cm). Platelet counts were 790 × 109/L with highest platelet
count of 1996 × 109/L in October 1996. Molecular biology analysis
were negative for the JAK2V617F, CALR and ASXL1 mutations. Bone
marrow histology showed a normal cellularity of about 40%, no
increase of erythropoiesis, and prominent increase of large to giant
megakaryocytes with hyperlobulated nuclei even stag-horn forms with
fine chromatin (Figure 8). Sporadically, small megakaryocytes with
less lobulated nuclei were present. Fine perivascular reticulin fibers
(RF grade 1) consistent with prefibrotic myelofibrosis MF 0.
Treatment consisted of low dose aspirin for the relief of microvascular
disturbances, pegylated interferon (IFN) was not tolerated and
subsequent treatment consisted of hydroxyurea from 1996 to 1999 was
followed by anagrelide from January 1999 untill she developed
refractory pancytopenic anemia and thrombocytopenia in 2004. Bone
marrow histology in 2004 showed a hypocellular bone marrow with
dysmorphic small to large megakaryocytes and only slight increase of
reticulin fibers RF grade 1 to 2 (Figure 9). Hematopioetic stem cell
transplantation (HSCT) in February 2005 of a matched (10/10)
unrelated donor and non-myeloablative conditioning (Busulfan-
Cytarabine-ATG) was followed by rapid engraftment and complete
hematological remission. She is more than 9 years alive and well in
2014 and beyond.
Discussion
In a European collaborative study, Jones et al. determined the MPL
mutation load in 138 W515K/L MPN cases: ET, n=99; MF, n=36;
unclassified MPN, n=331. The overall median W515K/L mutation
levels in ET was 21%, which were significantly lower than in MF
patients, 46% (P<.001, Figure 9). Twenty nine MPL515 homozygous
cases (mutation load more than 50% in 17 W515L and in 12 W515K
MPN cases) had a diagnosis of ET in 12, MF in 15 and accelerated/
transformed MPN in 2. The overall mutation levels in 106 MPLW515L
cases were lower, 25%, as compared to 37% in 32 MPLW515K cases
(P=0.02), thereby confirming the observations of Schnittger et al. in 35
cases with four different MPL515 mutations in ET or MF34. In this
German cohort of 324 JAK2 wild type ET, any MPLW515 mutation was
detected in 19 patients (5.9%), and of 104 JAK2 wild type MF, 10
MPLW515 mutations (9.6%) were detected. In addition two novel MPL
mutations W515R and W515K were found. We request in 2013 and
2014 the German MPN investigators Schnittger, Reiter and Kvasnicka
to collect BM biopsies for expert evaluation of the WHO defined
clinical molecular and pathological (WHO-CMP) [33-36] features in
their cohort of 35 MPL mutated ET and MF patients. Beer et al.
described bone marrow biopsies at diagnosis of 13 patients with MPL
mutations: 2 S505N, 2 W515K and 9 W515L MPN patients [30]. As
compared to JAK2V617F positive ET and JAK2/MPL wild type ET, the
bone marrow biopsies from the MPL mutant group were less cellular
(P<0.001 and P<0.003 with age). Both elytroid and granulocytic
cellularity were reduced in the MPL mutant group. (P<0.001)
indicating the absence of PV features. Overall, bone marrow histology
in MPL mutant patients revealed more isolated megakaryocytic
proliferation at diagnosis with a reduction of erythroid and overall
cellularity compared to JAK2V617F positive and JAK2/MPL wild type
ET (Figure 10) [37]. Serum EPO levels in MPL mutation patients were
significantly higher than in JAK2V617F positive ET (prodromal PV)
[35,36]. In contrast to JAK2V617F positive ET. Beer et al. found no
endogenous erythroid colonies (EEC) in any of 5 evaluated MPLW515L
cases (4 ET and 1 MF). At the basic research level Chaligne et al.
demonstrated that the two MPL mutations W515L and W515K induced
a spontaneous megakaryocyte growth in culture with an overall
normal response to thrombopoietin (TPO), but the erythroid
progenitors remained EPO dependent and did not show spontaneous
erythroid colony (EEC) formation (Figure 10) [21,33].
Figure 8: Bone marrow histology in normocellular ET carrying the
MPLW515L mutation showing giant megakaryocytes with
hyperlobulated stag-horn like nuclei charateristic for ET caused by
the MPLW515L/K mutation.
Figure 9: Evolution of acquired normocellular ET carrying the
MPLW515L mutation into pancytopenia (anemia and
thrombocytopenia) and a hypocelluar bone marrow with distorted
dysmorphic megakaryocytes and sliht increase of reticulin fibers RF
grade 1.
Figure 10: Isolated megakaryocytic proliferation at diagnosis with a
reduction of erythroid and overall cellularity compared to
JAK2V617F positive and JAK2/MPL wild type ET.
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